Roivant Sciences Ltd.

Alpha Score of 66 reflects moderate overall profile with strong momentum, strong value. Based on 2 of 4 signals — score is capped at 75 until remaining data ingests.

Roivant Sciences Ltd. is an American multinational healthcare company that develops transformative medicines and technologies by creating agile, focused subsidiaries called Vants. These Vants target specific therapeutic areas, including autoimmune diseases through Immunovant, severe autoimmune conditions via Priovant, and pulmonary diseases with Pulmovant. The company applies technology across drug discovery, development, and commercialization to accelerate the delivery of innovative therapies to patients. Roivant Sciences Ltd. maintains a broad pipeline of investigational drugs across multiple areas such as immunology, dermatology, rare diseases, and inflammatory conditions. Notable Vants include Kinevant for rare autoimmune and inflammatory diseases, and health technology units like Datavant for healthcare data sharing and Lokavant for clinical trial optimization. Founded in 2014 and headquartered in New York City with offices in Boston and Basel, Roivant Sciences Ltd. operates as a parent to these specialized entities, aligning incentives for efficient execution in the biopharmaceutical sector.